Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074420 · ClinicalTrials.gov registry record · Phase 3
A Study of Baricitinib (LY3009104) in Children With COVID-19
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT05074420: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT05074420 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 6 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05074420, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
Primary Outcome
PK: Overall AUC of Baricitinib in pediatric participants with COVID-19. Summarized data were reported in this outcome measure.
Interventions
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-12-21 |
| Est. Completion | 2024-11-04 |
| Phase | Phase 3 |
Why NCT05074420 stopped before completion
NCT05074420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Baricitinib is the first listed.
NCT05074420 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05074420 about?
NCT05074420 is a clinical study titled "A Study of Baricitinib (LY3009104) in Children With COVID-19". The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
What is the current status of trial NCT05074420?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2021-12-21. Estimated completion is 2024-11-04.
What interventions are being tested in trial NCT05074420?
The interventions under investigation include: Baricitinib (DRUG).
Who is sponsoring clinical trial NCT05074420?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05074420's enrollment target sits among peer trials
6 1995th of 2000 higher than 4 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI